대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Impact of the Baseline Anti-A/B Antibody Titer in ABO-Incompatible living Kidney Transplantation
저자	*Yong hun SIN
출판정보	2017; 2017(1):
키워드	Anti-A/B Antibody Titer , ABO-Incompatible living Kidney Transplantation
초록	Background/AIMS: We investigated the impact of the baseline anti-A/B antibody titer on the clinical outcome in ABO incompatible living kidney transplantation (LKT). Methods : We included 73 patients who had undergone ABO incompatible living kidney transplantation (LKT) at our hospital between 2009 and 2016. 24 patients with a baseline titer of ≥ 1: 256 were assigned to the high-titer group and 49 patients with a baseline titer of ≤ 1: 128 were assigned to the low-titer group. We compared the clinical outcomes of the two groups. . Retrospective analysis included blood group; baseline and post operative isoagglutinin titer; number of pretransplant plasmapheresis; and clinical outcomes including postoperative serum creatinine and glomerulitis plus ptcitis score on post operation 1 hour protocol biopsy Results : Preoperatively, rituximab administration and plasmapheresis were performed until the titer was reduced to ≤1:16.. high titer group needs more pretransplant plasmapheresis than low titer group(3.8 vs 6.6). The mean serum creatinine at 1(0.9mg/dl vs 1.0mg/dl), 3(1.0 mg/dl vs 1.1mg/dl) months did not differ significantly between low and high titer group(Table.1). Also, number of rejection(2/49 vs 2/24 cases) and graft loss(3/49 vs 2/24 cases) and patient loss(0/49 vs 1/24 case) did not differ significantly between low and high titer group(Table.1). Glomerulitis plus ptcitis score on postoperative 1 hour protocol biopsy shows no difference between low and high titer group( 0.5 vs 0.0) (Table.1). Conclusions : There is no correlation between high and low baseline anti-A/B antibody titers and the results of ABO-incompatible LKT was seen after rituximab and optimal pretransplant plasmapheresis with optimal immunosuppressant(tacrolimus , mycophenolate mofetil , steroids, IL-2 blocking agent(Simulect)) application.
원문(PDF)	PDF 원문보기

목록

위로가기